ArticleHuman vaccines & immunotherapeutics2025
Determinants of anti-HBs decline in rheumatoid arthritis patients undergoing rituximab therapy.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate longitudinal changes in hepatitis B surface antibody (anti-HBs) titers and determinants of seroprotection among patients with rheumatoid arthritis (RA) receiving Rituximab (RTX). Primary outcomes were titer trajectory and loss of seroprotection (<10 IU/L). Longitudinal change of anti-HBs titers was tested with Friedman and Wilcoxon signed-rank tests; seroprotection proportions with McNemar's test. Associations and predictors were examined using Spearman correlations and multivariable logistic regression (odds ratios [ORs], 95% CIs). Analyses were performed in SPSS 26.0 and cross-validated in Python (SciPy 1.11). Anti-HBs titers declined sharply within 3 months of RTX initiation (mean 463.2→218.3 IU/L;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.